Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.37 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 2/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18188785 | 1.00 | PIK3CD (0.39) | PIK3CDPIK3CGPIK3R1PIK3R2OGFRL1 | |
| SCHEMBL18188757 | 0.90 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R1OGFRL1 | |
| SCHEMBL16583453 | 0.90 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL18188693 | 0.90 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL18188758 | 0.90 | PIK3CD (0.48) | PIK3CDPIK3CGPIK3R1OGFRL1 | |
| SCHEMBL16583454 | 0.90 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R2 | |
| SCHEMBL18188794 | 0.83 | PIK3CD (0.44) | PIK3CDPIK3CG | |
| SCHEMBL18188792 | 0.83 | PIK3CD (0.44) | PIK3CDPIK3CG | |
| SCHEMBL18188765 | 0.82 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R1 | |
| SCHEMBL18188761 | 0.82 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518046-B2 | Substituted aminopyrimidine compounds and methods of use | CALITOR SCIENCES, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318913-A1 | SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, MYD88 | PIK3CD 2/4885PIK3CG 6/4885PIK3R1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.